Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07182227 · ClinicalTrials.gov registry record · Phase 1
PS-002 for the Treatment of IgA Nephropathy in Adults
A Phase 1 study of Immunoglobulin A (IgA) Nephropathy, sponsored by Purespring Therapeutics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 11
- Study locations
NCT07182227: Recruiting Phase 1 study of Immunoglobulin A (IgA) Nephropathy, sponsored by Purespring Therapeutics Limited.
NCT07182227 is a Phase 1 study of Immunoglobulin A (IgA) Nephropathy that is actively recruiting participants, run by Purespring Therapeutics Limited. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07182227, a Phase 1 study of Immunoglobulin A (IgA) Nephropathy, is actively recruiting participants, sponsored by Purespring Therapeutics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment. Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).
Conditions Studied
Interventions
- GENETIC PS-002
Study Locations (11)
Other
- Southmead Hospital - Bristol
- Cardiff and Vale University Health Board - Cardiff
- Royal Infirmary of Edinburgh Clinical Research Facility - Edinburgh
- The Royal London Hospital - London
Greater Manchester
- Manchester University NHS Foundation Trust - Manchester
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust - Manchester
Florida
- University of Miami Hospital - Miami
Maryland
- The Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan Hospital - Ann Arbor
Leicestershire
- Leicester General Hospital - Leicester
Nottinghamshire
- Nottingham University Hospitals NHS Trust - Nottingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
What NCT07182227 shows while recruiting
NCT07182227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Immunoglobulin A (IgA) Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which PS-002 is the first listed.
NCT07182227 lists 11 locations in 7 states (Other, Greater Manchester, Florida).
Frequently Asked Questions
What is clinical trial NCT07182227 about?
NCT07182227 is a clinical study titled "PS-002 for the Treatment of IgA Nephropathy in Adults". The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite rece...
What is the current status of trial NCT07182227?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-02. Estimated completion is 2029-09.
What conditions does trial NCT07182227 study?
This clinical trial studies the following conditions: Immunoglobulin A (IgA) Nephropathy.
What interventions are being tested in trial NCT07182227?
The interventions under investigation include: PS-002 (GENETIC).
Who is sponsoring clinical trial NCT07182227?
This trial is sponsored by Purespring Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07182227 being conducted?
This trial has 11 study locations across Florida, Maryland, Michigan, Greater Manchester, Leicestershire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A (IgA) Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07182227's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia